2015 Pediatric RX, Module 4: GI Drugs Update
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 0.75 NAPNAP contact hours, of which 0.75 is pharmacology content.
IMPORTANT: This continuing education activity is offered at a reduced rate to NAPNAP Members. You must be logged in using your NAPNAP Username and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity at the Non-Member rate, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any payment information.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: email@example.com
Copyright 2015 © by National Association of Pediatric Nurse Practitioners (NAPNAP)
Pediatric-focused advanced practice registered nurses
- Participants will have up‐to‐date information on current recommendations for use of GI drugs in the pharmacological management of common GI pathologies in children.
- Participants will be able to critically evaluate the safety and efficacy of GI drugs in children, such as proton pump inhibitors.
Teri Moser Woo, PhD, CPNP, CNL, FAANP, Associate Dean for Graduate Nursing Programs, Pacific Lutheran University, Tacoma, Wash.; Woodcreek Pediatrics, Puyallup, Wash.
Dr. Moser Woo has no financial relationships with any commercial entities to disclose, and will not discuss off label use and/or investigational use of individual drugs in this presentation.
- 0.75 Contact hours